Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Multiple epidermal growth factor-like domains protein 11 (MEGF11) is a transmembrane protein characterized by several epidermal growth factor (EGF)-like domains. It is involved in homotypic cell-cell adhesion and plays a critical role in retina layer formation and the spacing (mosaic) of specific neuron subtypes through repulsion mechanisms. MEGF11 is implicated in human diseases such as congenital myopathy and anemia and is proposed as a novel therapeutic target in oncology, particularly for triple-negative breast cancer, where its overexpression is linked to tumor recurrence, modulation of cytokine and chemokine cascades, and poor prognosis. MEGF11 may also have potential (predicted) scavenger receptor activity and participates in pathways involving AKT, mTOR, NF-κB, and CREB/AP-1, though it does not co-localize with EGFR or Gs protein in tumor cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple epidermal growth factor-like domains protein 11 (MEGF11).